| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446924 | European Journal of Cancer | 2011 | 8 Pages |
Abstract
The logistically complex MINDACT trial is feasible in a multinational setting. The proportion of discordant patients, the potential reduction in CT by using the genomic signature and compliance to treatment assignment are in accordance with the trial hypotheses.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Emiel Rutgers, Martine J. Piccart-Gebhart, Jan Bogaerts, Suzette Delaloge, Laura Van 't Veer, Isabel Teresa Rubio, Giuseppe Viale, Alastair M. Thompson, Rodolfo Passalacqua, Ulrike Nitz, Anita Vindevoghel, Jean-Yves Pierga, Peter M. Ravdin,